FibroGen Inc (FGEN) Given Average Rating of “Buy” by Brokerages

Shares of FibroGen Inc (NASDAQ:FGEN) have received an average rating of “Buy” from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $65.67.

A number of research analysts recently commented on the stock. ValuEngine raised shares of FibroGen from a “sell” rating to a “hold” rating in a report on Friday. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Finally, Mizuho reaffirmed a “hold” rating and issued a $61.00 price target on shares of FibroGen in a report on Thursday, November 9th.

FibroGen (FGEN) opened at $53.20 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen has a 1-year low of $22.70 and a 1-year high of $63.00. The company has a market cap of $4,582.51, a PE ratio of -26.08 and a beta of 1.74.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.13). FibroGen had a negative net margin of 120.00% and a negative return on equity of 47.36%. research analysts expect that FibroGen will post -1.75 earnings per share for the current year.

In other FibroGen news, Director Thomas F. Kearns, Jr. sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $45.22, for a total value of $813,960.00. Following the completion of the sale, the director now owns 156,564 shares of the company’s stock, valued at $7,079,824.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the firm’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $46.65, for a total transaction of $93,300.00. Following the completion of the sale, the director now directly owns 24,000 shares of the company’s stock, valued at approximately $1,119,600. The disclosure for this sale can be found here. In the last three months, insiders sold 328,917 shares of company stock valued at $16,142,651. 13.60% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. New York State Common Retirement Fund lifted its stake in FibroGen by 24.0% in the second quarter. New York State Common Retirement Fund now owns 67,700 shares of the biopharmaceutical company’s stock worth $2,187,000 after purchasing an additional 13,099 shares during the last quarter. FMR LLC increased its position in shares of FibroGen by 96.9% during the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after acquiring an additional 1,641,423 shares during the period. Schwab Charles Investment Management Inc. increased its position in shares of FibroGen by 22.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 333,660 shares of the biopharmaceutical company’s stock worth $17,951,000 after acquiring an additional 61,086 shares during the period. Legal & General Group Plc increased its position in shares of FibroGen by 31.1% during the third quarter. Legal & General Group Plc now owns 27,967 shares of the biopharmaceutical company’s stock worth $1,500,000 after acquiring an additional 6,634 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in shares of FibroGen by 12.2% during the second quarter. The Manufacturers Life Insurance Company now owns 46,284 shares of the biopharmaceutical company’s stock worth $1,495,000 after acquiring an additional 5,022 shares during the period. 57.11% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “FibroGen Inc (FGEN) Given Average Rating of “Buy” by Brokerages” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://sportsperspectives.com/2018/02/06/fibrogen-inc-fgen-given-average-rating-of-buy-by-brokerages.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply